—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Kiniksa Pharmaceuticals Ltd (KNSA) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for KNSA, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06
How it trades on rate days beta 0.60 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How KNSA has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.60 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Kiniksa Pharmaceuticals Ltd moved 0.60% on average · correlation 0.11 · higher than 61% of US names
  • Beta, last 3 months 1.95 more rate-sensitive lately than over the year
  • On the 10 worst bond days −0.53% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −0.97% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against KNSA on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Kiniksa Pharmaceuticals Ltd

KNSA in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Kiniksa Pharmaceuticals is a biopharmaceutical company that develops and sells therapies for autoinflammatory and cardiovascular conditions. Its approved medicine, Arcalyst, treats recurrent pericarditis, a chronic inflammation of the tissue around the heart, and cardiac sarcoidosis. The company is also testing KPL-387, a monoclonal antibody for the same pericarditis indication, in a combined Phase 2 and 3 trial, alongside KPL-116, an earlier antibody still in pre-clinical testing. Kiniksa operates across the United States, the United Kingdom and other markets, and is headquartered in London.
Where it sits in the stack
Kiniksa carries no seat in our index; it sits in the diary's healthcare sector, within the specialty and generic drug manufacturers group, outside the AI build-out stack the diary otherwise tracks.
Who it is priced against
The diary has not assigned Kiniksa to a peer group, so no comparison set is drawn from our coverage.
Why Closelooknet tracks it
Kiniksa holds no seat in our index and carries no Closelooknet score yet, and the diary has not quoted it in any edition.
What the diary watches
The diary watches how the Phase 2/3 trial of KPL-387 progresses, since a readout would extend Kiniksa's pericarditis treatment options beyond Arcalyst.

Kiniksa Pharmaceuticals Ltd (KNSA) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is Kiniksa Pharmaceuticals Ltd (KNSA)?

Kiniksa Pharmaceuticals Ltd trades as KNSA on the US exchange (US) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is KNSA in a Closelooknet index?

Not currently — Kiniksa Pharmaceuticals Ltd is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does KNSA trade against its moving averages?

Pullback inside an uptrend stack: Trades -0.6% vs the 50-day and +36.3% vs the 200-day average, 7.1% below the 52-week high and +119% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Kiniksa Pharmaceuticals Ltd compare with its peers?

Against its peer group (Drug Manufacturers - Specialty & Generic · US), Kiniksa Pharmaceuticals Ltd (KNSA) sits 7.1% below its 52-week high, 0.6% below its 50-day average; Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is 4.2% below, Dr. Reddy’s Laboratories Ltd ADR (RDY) is 19.5% below, Teva Pharma Industries Ltd ADR (TEVA) is 4.1% below. Put any of them next to KNSA in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Kiniksa Pharmaceuticals Ltd trade when bond yields rise?

Over the past year Kiniksa Pharmaceuticals Ltd had a beta of 0.60 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 61% of US names. On the 10 sessions in which long bonds fell most it moved −0.53% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Kiniksa Pharmaceuticals Ltd do?

Kiniksa Pharmaceuticals is a biopharmaceutical company that develops and sells therapies for autoinflammatory and cardiovascular conditions. Its approved medicine, Arcalyst, treats recurrent pericarditis, a chronic inflammation of the tissue around the heart, and cardiac sarcoidosis. The company is also testing KPL-387, a monoclonal antibody for the same pericarditis indication, in a combined Phase 2 and 3 trial, alongside KPL-116, an earlier antibody still in pre-clinical testing. The diary has not assigned Kiniksa to a peer group, so no comparison set is drawn from our coverage.

Where does Kiniksa Pharmaceuticals Ltd sit in the AI build-out?

Kiniksa carries no seat in our index; it sits in the diary's healthcare sector, within the specialty and generic drug manufacturers group, outside the AI build-out stack the diary otherwise tracks. Kiniksa holds no seat in our index and carries no Closelooknet score yet, and the diary has not quoted it in any edition.

What does this page show?

A live price chart with SMA overlays and drawing tools for KNSA, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.